“FreshOmega is the only marine oil that has been shown to elicit a clinically relevant reduction in circulatory oxLDL-GP complex in multiple human studies. LDL needs to be oxidized via ‘oxidative stress’ to form oxLDL which is shown to be both atherogenic and plaque forming. The latest research has shown that unlike native LDL, oxLDL binds to beta-2 glycoprotein-I (b2GPI) to form stable, non-dissociable oxLDL-GP complexes which have been implicated as pro-atherogenic antigens. They represent a major serologic risk factor and a significant contributor to the development of athero-thrombosis.”
-Dr. Bomi Framoroze is a discovery scientist with over 35 worldwide patents and publications in life sciences and software research. He has 25 years of research experience in the discovery of new active ingredients and biochemical development.